Skip to main content
BIOA
NASDAQ Life Sciences

BioAge Labs' Q1 Collaboration Revenue Soars Past Estimates on Strong Novartis Partnership

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$17.72
Mkt Cap
$791.169M
52W Low
$3.67
52W High
$24
52W Position info
383% above low
Off High info
26% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

BIOA has more than doubled off its 52-week low of $3.67.

Summary

BioAge Labs reported Q1 collaboration revenue of $2.77 million, significantly beating analyst estimates of $1.32 million. This strong performance was primarily driven by increased employee effort under its partnership with Novartis. This news comes on the same day as the company's 10-Q filing, which also highlighted positive Phase 1 clinical trial results for BGE-102 and a $132.3 million follow-on public offering. The substantial revenue beat from the Novartis collaboration is a positive indicator of the partnership's progress and potential for future milestone payments, which are crucial for a development-stage biotech. While the company's net loss widened due to increased R&D for its BGE-102 and APJ agonist programs, the successful financing ensures operations are funded through 2029. Investors will monitor the continued progress of the Novartis collaboration and the clinical development of BGE-102 and APJ agonist programs.

At the time of this announcement, BIOA was trading at $17.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $791.2M. The 52-week trading range was $3.67 to $24.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

BIOA - Latest Insights

BIOA
Nov 05, 2026, 4:40 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.48
Real-time Price: $4.84 info
Change: -$0.640 (-12%) info
Market Cap: $222.899M info
BIOA
Nov 05, 2026, 4:30 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.48
Real-time Price: $4.84 info
Change: -$0.640 (-12%) info
Market Cap: $222.899M info
BIOA
Sep 08, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $9.75
Real-time Price: $4.84 info
Change: -$4.91 (-50%) info
Market Cap: $222.899M info
BIOA
Aug 05, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.98
Real-time Price: $4.84 info
Change: -$6.14 (-56%) info
Market Cap: $222.899M info
BIOA
Aug 05, 2026, 4:55 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.98
Real-time Price: $4.84 info
Change: -$6.14 (-56%) info
Market Cap: $222.899M info